<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38623" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Glimepiride</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Trerattanavong</surname>
            <given-names>Kentaro</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kentaro Trerattanavong declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38623.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Glimepiride is a medication used in the management and treatment of type 2 diabetes mellitus. It is in the sulfonylurea class of drugs. This activity outlines the indications, mechanism of action, and contraindications for glimepiride as a valuable agent in managing type 2 diabetes mellitus. This activity will also highlight the mechanism of action, adverse event profile, and other key factors (e.g., dosing, pharmacodynamics, monitoring, relevant interactions) pertinent for interprofessional healthcare team members managing patients with type 2 diabetes mellitus and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of glimepiride.</p></list-item><list-item><p>Describe the possible adverse effects of glimepiride.</p></list-item><list-item><p>Review appropriate monitoring methods for patients on glimepiride, including management of complications of treatment.</p></list-item><list-item><p>Explain the importance of collaboration and communication amongst the interprofessional team and patients to improve patient outcomes when receiving glimepiride therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38623&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38623">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38623.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Glimepiride is a second-generation sulfonylurea&#x000a0;that&#x000a0;received FDA approval in 1995 to use for the improvement of glycemic control in adults with type 2 diabetes mellitus.<xref ref-type="bibr" rid="article-38623.r1">[1]</xref> It can serve as a second-line drug in the treatment of type 2 diabetes mellitus in combination therapy in conjunction with metformin in patients who do not have any form of atherosclerotic cardiovascular disease and not at their target hemoglobin A1c.<xref ref-type="bibr" rid="article-38623.r2">[2]</xref>&#x000a0;Additionally, it is worth noting that glimepiride is the only sulfonylurea approved by the FDA for combination therapy with insulin in patients that are not responsive to combination therapy.<xref ref-type="bibr" rid="article-38623.r1">[1]</xref>&#x000a0;Glimepiride is also prescribable as monotherapy in patients that are unable to tolerate metformin.<xref ref-type="bibr" rid="article-38623.r3">[3]</xref>&#x000a0;</p>
        <p>Glimepiride is sometimes referred to as a third-generation sulfonylurea as it has a better safety profile and has a prolonged duration of action of up to 24 hours.<xref ref-type="bibr" rid="article-38623.r4">[4]</xref><xref ref-type="bibr" rid="article-38623.r1">[1]</xref>&#x000a0;Glimepiride has few cardiovascular effects compared to other sulfonylureas, which are primarily notorious for their effects on myocytes due to the blockade of&#x000a0;ATP-dependent potassium channels.<xref ref-type="bibr" rid="article-38623.r5">[5]</xref>&#x000a0;Furthermore, unlike other sulfonylureas, glimepiride does not affect the&#x000a0;ischemic preconditioning of cardiac myocytes, defined as an adaptive physiological mechanism in response to an ischemic event to delay infarction and limit cardiac tissue damage. Researchers postulate that glimepiride selectively blocks sarcolemmal ATP-dependent potassium channels in cardiac myocytes over mitochondrial potassium channels, maintaining myocardial preconditioning.<xref ref-type="bibr" rid="article-38623.r6">[6]</xref>&#x000a0;This difference from other drugs in the class means that the use of glimepiride may be safer and more ideal in patients with cardiovascular comorbidities.<xref ref-type="bibr" rid="article-38623.r1">[1]</xref></p>
      </sec>
      <sec id="article-38623.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Glimepiride is an insulin secretagogue and, like other sulfonylureas, is only effective in patients with residual pancreatic beta-cell activity. They act at ATP-dependent potassium channels on the cell membrane of&#x000a0;pancreatic beta cells, causing iatrogenic depolarization by preventing potassium from exiting the cell. The depolarization activates voltage-dependent calcium channels on the cell membrane, leading to a rise in intracellular calcium and subsequent exocytosis of insulin into the bloodstream.<xref ref-type="bibr" rid="article-38623.r7">[7]</xref>&#x000a0;Insulin then acts on cell membrane receptors triggering GLUT-4 expression and the movement of glucose into the cell, lowering blood glucose levels. Additionally, research has shown that glimepiride interacts with Epac3, a nucleotide exchanger that mediates the exocytosis of insulin granules.<xref ref-type="bibr" rid="article-38623.r8">[8]</xref><xref ref-type="bibr" rid="article-38623.r9">[9]</xref><xref ref-type="bibr" rid="article-38623.r10">[10]</xref>&#x000a0;Glimepiride's effectiveness was highlighted in a study conducted on healthy volunteers. Results demonstrated a linear relationship between serum glimepiride and insulin release in euglycemic and hyperglycemic conditions.<xref ref-type="bibr" rid="article-38623.r11">[11]</xref>&#x000a0;&#x000a0;</p>
      </sec>
      <sec id="article-38623.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The&#x000a0;standard initial&#x000a0;dose of glimepiride is between 1&#x000a0;and 2 mg once daily, taken orally before the patient's first meal. Patients who are prone to hypoglycemia should be started at 1 mg once daily and titrated slowly to an appropriate dose. Following initial therapy, the&#x000a0;standard&#x000a0;maintenance dosage is at 1&#x000a0;to 4 mg once daily; however, this can be gradually titrated up to 8 mg once daily, depending on the patient's blood glucose and hemoglobin A1c levels. It is important to note that current guidelines do not have a fixed dosage regimen for glimepiride, and the dose requires adjustment according to the patient's blood glucose levels and hemoglobin A1c.<xref ref-type="bibr" rid="article-38623.r1">[1]</xref>&#x000a0;</p>
        <p>When used for combination therapy with metformin, the clinician should attempt to identify the minimum effective dose of each drug as the risk of hypoglycemia increases with the use of metformin with glimepiride.<xref ref-type="bibr" rid="article-38623.r1">[1]</xref>&#x000a0;Dual therapy of glimepiride with insulin is an option in patients with chronic type 2 diabetes whose initial response to blood glucose-lowering medication has diminished. The fasting glucose level requirement for providing this therapy is greater than 150 mg/dL. In this case, patients should start on glimepiride at 8 mg once daily with subsequent adjustments of insulin administration depending on the patient's blood glucose.</p>
      </sec>
      <sec id="article-38623.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Glimepiride, like other sulfonylureas, has multiple adverse effects, the most deadly and notorious being its metabolic effects. As glimepiride increases endogenous insulin secretion, this can lead to hypoglycemia. In patients with long-standing diabetes mellitus, hypoglycemic unawareness can manifest where the autonomic symptoms of hypoglycemia are not experienced by the patient, leading to neuroglycopenia symptoms and potential hypoglycemic coma. This situation is particularly dangerous in drivers or those involved in skilled tasks, especially if other hypoglycemic agents are in concomitant use. Weight gain is another significant side effect of sulfonylureas such as glimepiride, which can&#x000a0;interfere with management as weight loss is often a major target in the treatment of diabetes.&#x000a0;Other adverse effects include vomiting,&#x000a0;abdominal&#x000a0;pain, diarrhea, erythema multiforme, and exfoliative dermatitis.<xref ref-type="bibr" rid="article-38623.r1">[1]</xref><xref ref-type="bibr" rid="article-38623.r12">[12]</xref></p>
      </sec>
      <sec id="article-38623.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications for glimepiride include the following patient groups and conditions:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic ketoacidosis</p>
          </list-item>
          <list-item>
            <p>Type I diabetes mellitus</p>
          </list-item>
          <list-item>
            <p>Hypersensitivity to glimepiride</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-38623.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitoring methods for glimepiride include frequent self-glucose monitoring and hemoglobin A1c monitoring every 3 to 6 months. In those with renal pathology, monitoring of glomerular filtration rate may be recommended as glimepiride is primarily excreted via the kidneys.&#x000a0;</p>
      </sec>
      <sec id="article-38623.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>In cases of overdose of sulfonylureas such as glimepiride, hypoglycemia can occur. It is essential to recognize the signs and symptoms of hypoglycemia, which can fall into the following two categories:</p>
        <list list-type="order">
          <list-item>
            <p>Autonomic symptoms such as tremor, palpitations, nausea, tachycardia, diaphoresis, and anxiety</p>
          </list-item>
          <list-item>
            <p>Neuroglycopenic symptoms such as confusion, fatigue, headache, drowsiness, coma, and seizures.</p>
          </list-item>
        </list>
        <p>Rapid recognition and reversal of hypoglycemia are essential in improving prognosis in those that have overdosed on glimepiride.<xref ref-type="bibr" rid="article-38623.r13">[13]</xref>&#x000a0;Initial management is intravenous dextrose; however, this is quickly switched to octreotide (long-acting somatostatin analog) as many patients will have sufficient pancreatic function to stimulate endogenous insulin production in response leading to a cycle of dextrose infusion and rebound hypoglycemia. Additionally, activated charcoal should be given as soon as possible for decontamination. In an emergency or pre-hospital setting, intramuscular injections of glucagon can temporarily increase blood glucose via physiological glycogenolysis and gluconeogenesis. However, as glucagon stimulates insulin release, this is not recommended.<xref ref-type="bibr" rid="article-38623.r14">[14]</xref></p>
      </sec>
      <sec id="article-38623.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing type 2 diabetes mellitus involves an interprofessional healthcare team approach involving various healthcare team members, including but not limited to the endocrinologist, family/primary care clinician (MDs, DOs, PAs, NPs), diabetes specialist nurse, podiatrist, and pharmacist. Its management involves the utilization of drugs that control blood glucose, which include glimepiride. Glimepiride is a second-line, FDA-approved drug to be used either in combination with metformin or as a monotherapy. Sulfonylureas augment and increase insulin release from the pancreas and, although effective, poses a threat&#x000a0;to patient safety if used inappropriately. Sufficient&#x000a0;communication is essential in delivering optimal care to patients, including providing information in aspects such as time and frequency of administration and associated sick day rules. Through a coordinated interprofessional team effort, diabetes management, including the use of glimepiride, can achieve better patient outcomes and limit the potential for therapeutic failure or adverse events. [Level 5]</p>
      </sec>
      <sec id="article-38623.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38623&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38623">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38623/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38623">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38623.s11">
        <title>References</title>
        <ref id="article-38623.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basit</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fawwad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected].</article-title>
            <source>Vasc Health Risk Manag</source>
            <year>2012</year>
            <volume>8</volume>
            <fpage>463</fpage>
            <page-range>463-72</page-range>
            <pub-id pub-id-type="pmid">23028231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>8. Pharmacologic Approaches to Glycemic Treatment: <italic>Standards of Medical Care in Diabetes-2018</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>41</volume>
            <issue>Suppl 1</issue>
            <fpage>S73</fpage>
            <page-range>S73-S85</page-range>
            <pub-id pub-id-type="pmid">29222379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bahendeka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Md</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Orabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramaiya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al Shammari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abhayaratna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Mahalingam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Askheta</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>A Rahim</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Eliana</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Chaudhary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ngugi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mbanya</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Aye</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Latt</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Akanov</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Tandon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Unnikrishnan</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Madhu</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Jawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bajaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>132</fpage>
            <page-range>132-157</page-range>
            <pub-id pub-id-type="pmid">29535952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madsen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>K&#x000e4;hler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>K&#x000e4;hler</surname>
                <given-names>LKA</given-names>
              </name>
              <name>
                <surname>Madsbad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gnesin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Metzendorf</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hemmingsen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Metformin and second- or third-generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2019</year>
            <month>Apr</month>
            <day>18</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD012368</fpage>
            <pub-id pub-id-type="pmid">30998259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000e9;gh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Papp</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Haemodynamic and other effects of sulphonylurea drugs on the heart.</article-title>
            <source>Diabetes Res Clin Pract</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>31 Suppl</volume>
            <fpage>S43</fpage>
            <page-range>S43-53</page-range>
            <pub-id pub-id-type="pmid">8864640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mocanu</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Maddock</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Standen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Yellon</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.</article-title>
            <source>Circulation</source>
            <year>2001</year>
            <month>Jun</month>
            <day>26</day>
            <volume>103</volume>
            <issue>25</issue>
            <fpage>3111</fpage>
            <page-range>3111-6</page-range>
            <pub-id pub-id-type="pmid">11425777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Briscoe</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SN</given-names>
              </name>
            </person-group>
            <article-title>The role of glimepiride in the treatment of type 2 diabetes mellitus.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>225</fpage>
            <page-range>225-35</page-range>
            <pub-id pub-id-type="pmid">20055691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kashima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shibasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miyazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Seino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion.</article-title>
            <source>J Biol Chem</source>
            <year>2001</year>
            <month>Dec</month>
            <day>07</day>
            <volume>276</volume>
            <issue>49</issue>
            <fpage>46046</fpage>
            <page-range>46046-53</page-range>
            <pub-id pub-id-type="pmid">11598134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozaki</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shibasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kashima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sunaga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Iwanaga</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Seino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>cAMP-GEFII is a direct target of cAMP in regulated exocytosis.</article-title>
            <source>Nat Cell Biol</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>2</volume>
            <issue>11</issue>
            <fpage>805</fpage>
            <page-range>805-11</page-range>
            <pub-id pub-id-type="pmid">11056535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Katoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shibasaki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sunaga</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Seino</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs.</article-title>
            <source>Science</source>
            <year>2009</year>
            <month>Jul</month>
            <day>31</day>
            <volume>325</volume>
            <issue>5940</issue>
            <fpage>607</fpage>
            <page-range>607-10</page-range>
            <pub-id pub-id-type="pmid">19644119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldberg</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Holvey</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.</article-title>
            <source>Diabetes Care</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>849</fpage>
            <page-range>849-56</page-range>
            <pub-id pub-id-type="pmid">8842603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schianca</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Maffioli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bigliocca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mella</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Corlian&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fra</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Bartoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Derosa</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Sulfonylureas and their use in clinical practice.</article-title>
            <source>Arch Med Sci</source>
            <year>2015</year>
            <month>Aug</month>
            <day>12</day>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>840</fpage>
            <page-range>840-8</page-range>
            <pub-id pub-id-type="pmid">26322096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soderstrom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Little</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Toxicology case of the month: oral hypoglycaemic overdose.</article-title>
            <source>Emerg Med J</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>23</volume>
            <issue>7</issue>
            <fpage>565</fpage>
            <page-range>565-7</page-range>
            <pub-id pub-id-type="pmid">16794105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38623.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stassinos</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Treatment of sulfonylurea and insulin overdose.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>81</volume>
            <issue>3</issue>
            <fpage>496</fpage>
            <page-range>496-504</page-range>
            <pub-id pub-id-type="pmid">26551662</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
